



CCM DUOPHARMA BIOTECH BERHAD (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 MARCH 2018**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 31/3/2018 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 31/3/2017 RM'000	CURRENT YEAR TO DATE 31/3/2018 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 31/3/2017 RM'000
Revenue	133,259	120,994	133,259	120,994
Cost of Sales	(80,618)	(78,704)	(80,618)	(78,704)
Gross Profit	52,641	42,290	52,641	42,290
Other operating income	67	101	67	101
Distribution costs	(19,895)	(16,399)	(19,895)	(16,399)
Administration expenses	(18,246)	(13,651)	(18,246)	(13,651)
Other operating expenses	(299)	(567)	(299)	(567)
Profit from operations	14,268	11,774	14,268	11,774
Finance income	445	715	445	715
Finance costs	(1,458)	(1,313)	(1,458)	(1,313)
Profit before taxation	13,255	11,176	13,255	11,176
Taxation	(2,608)	(2,558)	(2,608)	(2,558)
Profit after tax for the period	10,647	8,618	10,647	8,618
Other comprehensive income				
Foreign currency translation differences for foreign operations	135		135	
Total other comprehensive income for the period	10,782	8,618	10,782	8,618
Profit attributable to:				
Shareholders of the Company	10,647	8,618	10,647	8,618
Minority interest	-	-	-	-
	10,647	8,618	10,647	8,618
Total comprehensive income attributable to:				
Shareholders of the Company	10,782	8,618	10,782	8,618
Minority interest	-	-	-	-
	10,782	8,618	10,782	8,618
Earnings per share (sen)				
Basic (based on weighted average)	3.82	3.43	3.82	3.43
Diluted (based on weighted average)	3.82	3.43	3.82	3.43

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2017 and the accompanying explanatory notes attached to the interim financial statements.